RxDoctor Payments Data

Eola Bentley-Force

Family · Palm Desert, CANPI 1124340922

Payments from drug & device makers

$2,748in general payments, 2019–2025

Across 101 payments — averaging $27.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$321
  • Boston Scientific$320
  • Biohaven Pharmaceuticals, Inc.$282
  • AbbVie$266
  • Nevro Corp.$208
  • Si-bone, Inc.$185
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$2,72599%
  • Education$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,748 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$75,714
Medicare patients
97
Services billed
652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl92$91,458
Hysingla ErHydrocodone Bitartrate40$40,342
Xtampza ErOxycodone Myristate32$21,498
Buprenorphine63$15,832
OxycontinOxycodone Hcl20$12,065
MovantikNaloxegol Oxalate26$10,697
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen268$10,696
LinzessLinaclotide13$9,590
NucyntaTapentadol Hcl13$7,045
Gabapentin66$5,180
Oxycodone Hcl135$4,567
Hydrocodone Bitartrate ErHydrocodone Bitartrate14$3,837
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen120$3,570
Morphine Sulfate ErMorphine Sulfate108$2,252
Fentanyl20$1,467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$321$120,000137 claims
Redhill Biopharma Inc.Movantik$110$10,69726 claims
AbbVieLinzess$266$9,59013 claims
Almatica Pharma LLCSertraline Hcl$55$21032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Palm Desert

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →